DelveInsight’s, “Alzheimer’s Disease Pipeline Insight” report provides comprehensive insights about 110+ companies and 120+ pipeline drugs in Alzheimer’s-disease pipeline landscape. It covers the Alzheimer’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Alzheimer’s Disease therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Alzheimer’s Disease Treatment Landscape. Click here to read more @ Alzheimer’s Disease Pipeline Outlook

 

Key Takeaways from the Alzheimer’s Disease Pipeline Report

• In January 2025:- Novo Nordisk- The study is being conducted to understand how the medicine, semaglutide, affects the immune system and other biological processes in people with Alzheimer’s disease. Semaglutide is a medicine that doctors can prescribe in some countries for the treatment of type 2 diabetes and excess body weight.
• In January 2025:- Hoffmann-La Roche:- The purpose of this study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of multiple-ascending intravenous (IV) doses of RO7126209 in participants with prodromal or mild to moderate Alzheimer’s disease (AD), who are amyloid positive based on amyloid positron emission tomography (PET) scan.
• In January 2025:- Bigespas Ltd:- Multicenter Randomized Double-blind Placebo-controlled Three-arm Parallel-group Clinical Study to Evaluate the Efficacy and Safety of DMB-I in the Treatment of Dementia Associated With Alzheimer’s Disease. The purpose of this study is to assess the efficacy and safety of DMB-I for the treatment of patients with Alzheimer type dementia.
• In January 2025:- Eisai Inc.:- The primary objective of the study is to determine the dose response of E2814, when concurrently administered with lecanemab, on the change from baseline at 6 months in cerebrospinal fluid (CSF) microtubule-binding region (MTBR)-tau-243 in participants with early Alzheimer’s disease (AD).
• DelveInsight’s Alzheimer’s Disease pipeline report depicts a robust space with 110+ active players working to develop 120+ pipeline therapies for Alzheimer’s Disease treatment.
• The leading Alzheimer’s Disease Companies such as AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Cassava Sciences, BioVie Inc., Novo Nordisk, Alector Inc., Longeveron Inc., TrueBinding, Inc., VT BIO, Luye Pharma Group Ltd., Lexeo Therapeutics, Merck Sharp & Dohme LLC, Regeneration Biomedical, Alnylam Pharmaceuticals, Sinotau Pharmaceutical Group, Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd and others.
• Promising Alzheimer’s Disease Therapies such as Aricept, INM-176, SAR110894, Donepezil, CPC-201, ENA713, Remternetug, and others.

 

Stay informed about the cutting-edge advancements in Alzheimer’s Disease treatments. Download for updates and be a part of the revolution in care @ Alzheimer’s Disease Clinical Trials Assessment

 

Alzheimer’s Disease Emerging Drugs Profile

 

• AR1001: AriBio Co., Ltd.

AR1001 is a selective inhibitor of phosphodiesterase 5. This new pyrrolo-pyrimidinone was first developed for treatment of erectile dysfunction in South Korea, and is now being tested for Alzheimer’s Disease. Its maker claims AR1001 to be 10-fold more potent at inhibiting PDE5, and better at entering the brain, than approved PDE5 inhibitors, including sildenafil.

 

• NE3107: BioVie

NE3107 is an orally available small molecule with potential anti-inflammatory and insulin-sensitizing properties that can cross the blood-brain barrier. It was originally developed by NeurMedix and acquired by BioVie in April. The experimental molecule works by blocking the activation of two major regulators of inflammatory pathways: extracellular signal regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB).

 

• LY3372689: Eli Lilly & Co.

LY3372689 is an orally active O-GlcNAcase (OGA) enzyme inhibitor. O-GlcNAcylation, i.e., addition of N-acetylglucosamine to serine and threonine residues, is a post-translational modification that regulates the function of many proteins. In particular, N-GlcNAcylation of tau reduces its propensity to form toxic aggregates. OGA catalyzes removal of O-GlcNAc. OGA inhibitors promote tau glycosylation, prevent aggregation, and appear to stabilize tau in a soluble, nonpathogenic form. LY3372689 can be used for tauopathies research, including Alzheimer’s disease. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Alzheimer’s disease.

 

• CT1812: Cognition Therapeutics

Cognition Therapeutics isdeveloping CT1812, an oral, brain-penetrant, small molecule therapeutic, which has been shown to protect neurons and synapses by preventing the binding of toxic oligomers. CT1812 acts as a neuroprotective agent both by shielding neurons and synapses from oligomer binding and by preventing oligomers from attaching to synapses in the first place. CT1812 may help mitigate the neurotoxic effects, slowing cognitive decline and progression of Alzheimer’s disease. Currently, the drug is in the Phase II stage of development to treat Alzheimer’s-disease.

 

• ABBV-916: AbbVie Inc.

ABBV-916 anti-AβpE3 (N-terminal truncated, pyroglutamate-modified at amino acid position 3, amyloid beta) is a monoclonal antibody being investigated for the treatment of Alzheimer’s Disease. The drug candidate is administered through intravenous route as an infusion. Currently, the drug is in the Phase II stage of development to treat Alzheimer’s-disease.

 

• ALX-001: Allyx Therapeutics, Inc.

ALX-001 (previously BMS-984923) is a silent allosteric modulator of mGluR5, a first-in-class compound that selectively blocks the pathogenic activation of the receptor while preserving the physiological glutamate signaling that is required for normal cognition. ALX-001 has a wide therapeutic window that can saturate receptor binding while avoiding on-target toxicity observed with negative allosteric modulators. Currently, the drug is in the Phase I stage of development to treat Alzheimer’s disease.

 

Learn more about Alzheimer’s Disease Drugs opportunities in our groundbreaking Alzheimer’s Disease research and development projects @ Alzheimer’s Disease Unmet Needs

 

Alzheimer’s Disease Companies

AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Cassava Sciences, BioVie Inc., Novo Nordisk, Alector Inc., Longeveron Inc., TrueBinding, Inc., VT BIO, Luye Pharma Group Ltd., Lexeo Therapeutics, Merck Sharp & Dohme LLC, Regeneration Biomedical, Alnylam Pharmaceuticals, Sinotau Pharmaceutical Group, Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd and others.

 

Alzheimer’s-disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Alzheimer’s Disease Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Discover the latest advancements in Alzheimer’s Disease treatment by visiting our website. Stay informed about how we’re transforming the future of neurology @ Alzheimer’s Disease Market Drivers and Barriers, and Future Perspectives

 

Scope of the Alzheimer’s Disease Pipeline Report

• Coverage- Global
• Alzheimer’s Disease Companies- AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Cassava Sciences, BioVie Inc., Novo Nordisk, Alector Inc., Longeveron Inc., TrueBinding, Inc., VT BIO, Luye Pharma Group Ltd., Lexeo Therapeutics, Merck Sharp & Dohme LLC, Regeneration Biomedical, Alnylam Pharmaceuticals, Sinotau Pharmaceutical Group, Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd and others.
• Alzheimer’s Disease Therapies- Aricept, INM-176, SAR110894, Donepezil, CPC-201, ENA713, Remternetug, and others.
• Alzheimer’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Alzheimer’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Alzheimer’s Disease Pipeline on our website @ Alzheimer’s Disease Emerging Drugs and Companies

 

Table of Content

1. Introduction
2. Executive Summary
3. Alzheimer’s-disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Alzheimer’s-disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. AR1001: AriBio Co., Ltd.
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. LY3372689: Eli Lilly & Co.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ALX-001: Allyx Therapeutics, Inc.
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Alzheimer’s-disease Key Companies
21. Alzheimer’s-disease Key Products
22. Alzheimer’s-disease- Unmet Needs
23. Alzheimer’s-disease- Market Drivers and Barriers
24. Alzheimer’s-disease- Future Perspectives and Conclusion
25. Alzheimer’s-disease Analyst Views
26. Alzheimer’s-disease Key Companies
27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/knee-reconstruction-devices-market